Lineage Cell Therapeutics (LCTX) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 26, 2025, at the company’s headquarters in Carlsbad, CA.

• Shareholders of record as of April 28, 2025, are eligible to vote on key proposals.

• Proxy materials, including the notice, proxy statement, and annual report, are available online and by request.

Voting matters and shareholder proposals

• Election of seven directors to serve until the 2026 annual meeting.

• Ratification of Moss Adams LLP as independent auditor for fiscal year ending December 31, 2025.

• Advisory vote on executive compensation (say-on-pay).

• Approval of an amendment to the 2021 Equity Incentive Plan to add 19,500,000 common shares.

• Board recommends voting in favor of all proposals.

Board of directors and corporate governance

• Seven director nominees: Dipti Amin, Deborah Andrews, Neal C. Bradsher, Brian M. Culley, Anula Jayasuriya, Michael H. Mulroy, Angus C. Russell.